Treatment of metastatic pheochromocytoma and paraganglioma with 131I-meta-iodobenzylguanidine (MIBG)

Endocrinologist

Volumn 13, Issue 4, 2003, Pages 321-333

  Kaltsas, Gregory A ^a   Mukherjee, J J ^b,e   Foley, R ^c   Britton, K E ^d   Grossman, Ashley B ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Catecholamine producing tumors; MIBG; Paraganglioma; Pheochromocytoma; Radionuclides

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ADRENERGIC NEURON BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; LABETALOL; METIROSINE; PENTETREOTIDE IN 111; POTASSIUM IODIDE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE; YTTRIUM 90;

BETA RADIATION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHEMICAL STRUCTURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RETENTION; DRUG SAFETY; DRUG UPTAKE; DRUG WITHDRAWAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOTENSION; LEUKOPENIA; LIVER FAILURE; MUCOSA INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PHYSICAL CHEMISTRY; PREMATURE OVARIAN FAILURE; QUALITY OF LIFE; RADIATION DOSE; RADIODIAGNOSIS; REVIEW; SCINTIANGIOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0042626461     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TEN.0000084154.02341.ad     Document Type: Review

References (86)

1. Solcia E, Rindi G, Paolotti D, et al. Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann Oncol. 1999;10:S9-S15.
2. Shapiro B, Fig LM. Management of pheochromocytoma. End Metab Clin North Am. 1989;18:443-481.
3. 131I-MIBG therapy of neural crest tumours. Antic Res. 1997;17:1823-1832.
4. Bravo EL. Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endo Rev. 1994;15:356-368.
5. Grossman AB, Kaltsas GA. Adrenal medulla. Physiology and pathology. In: Besser GMB, Thomer MO, eds. Clinical Endocrinology, 3rd ed. London: Mosby, 2002:223-237.
6. Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment and follow-up. Surg Oncol Clin North Am. 1998;7:765-789.
7. Orchard T, Grant CS, van Heerden JA, et al. Pheochromocytoma - continuing evolution of surgical therapy. Surgery. 1993;114:1153-1158.
8. Schlumberger M, Gicquel C, Lumbroso J. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest. 1992;15:631-642.
9. Shapiro B, Sisson JC, Lloyd R, et al. Malignant pheochromocytoma: clinical, biochemical, and scintigraphic characterization. Clin Endocrinol (Oxf). 1984;20:189-203.
10. Shapiro B, Copp JE, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine for the localization of suspected pheochromocytoma: experience in 400 cases. J Nucl Med. 1985;26:576-585.
11. 131I-MIBG scintigraphy. Clin Nucl Med. 1990;15:101-104.
12. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648-658.
13. Mornex R, Badet C, Peyrin L. Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990. J Endocrinol Invest. 1992;15:643-649.
14. Averbach SD, Steakley CS, Young RN, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109:267-273.
15. Kaltsas G, Mukherjee JJ, Plowman PN, et al. The role of chemotherapy in the non-surgical management of malignant neuroendocrine tumours. Clin Endocrinol. 2001;55:575-587.
16. Robinson RG, DeQuattro V, Grushkin CM, et al. Childhood pheochromocytoma: treatment with alpha methyltyrosine for resistant hypertension. J Pediatr. 1977;91:143-147.
17. Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma. Chromatin granule transmitters and response to treatment. Hypertension. 2000;36:1045-1052.
18. Iwabuchi M, Oki Y, Nakamura H. Palliative treatment for malignant pheochromocytoma: symptomatic palliation of two cases. Intern Med. 1999;38:17-21.
19. Arnold R, Frank M, Kadjan U. Management of gastroenteropancreatic endocrine tumours: the place of somatostatin analogues. Digestion. 1994;55:107-113.
20. Kaltsas G, Mukherjee JJ, Grossman AB. The value of radiolabeled MIBG and octreotide in the diagnosis and management of neuroendocrine tumors. Ann Oncol. 2001;12(suppl 2):S47-S50.
21. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogues in the diagnosis and treatment of tumours. Endo Rev. 1991; 12:561-581.
22. 131I-metaiodobenzylguanidine. Nucl Med Commun. 1993;14:856-861.
23. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 1995; XXV:272-278.
24. Sisson JC, Shapiro B, Beierwalters WH, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984;24:197-206.
25. Sisson JC, Wieland DM, Sherman P. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987;28:1620-1624.
26. Sisson JC, Bolgos G, Johnson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am Heart J. 1991;121: 1119-1123.
27. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981;305:12-17.
28. Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (1-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med. 1983;24:672-682.
29. Roelants V, Goulios C, Beckers C, et al. Iodine-131-MIBG scintigraphy in adults: interpretation revisited? J Nucl Med. 1998;39:1007-1012.
30. Troncone L, Rufini V, Montemaggi P, et al. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years experience. Eur J Nucl Med. 1990;16:325-335.
31. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med. 1994;21:561-581.
32. Shapiro B. Summary, conclusions and future directions of [1311]metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med. 1991;35:357-363.
33. Chatal JF, Le Bodic MF, Kraeber-Bodere F, et al. Nuclear medicine applications for neuroendocrine tumors. World J Surg. 2000;24:1285-1289.
34. 131I-MIBG). Clin Endocrinol. 2001;55:47-60.
35. Buhl T, Mortensen J, Kjaer A. I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma: a case report. Clin Nucl Med. 2002;27:183-185.
36. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med. 1995;36:1-6.
37. Kopf D, Bockisch A, Steiner H, et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol. 1997;46:39-44.
38. 111In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693.
39. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine (MIBG) radionuclides in the diagnosis and localisation of advanced neuroendocrine tumours. J Clin Endocrinol Metab. 2001;86:895-902.
40. Krenning EP, De Jong M, Kooij PPM, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23-S29.
41. Borbardieri E, Maccauro M, de Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumors. Ann Oncol. 2001;12:S51-S61.
42. 3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368-371.
43. Troncone L, Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med. 1999;43:344-355.
44. Krempf M, Lumbroso J, Mornex R, et al. Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicentric study. J Nucl Biol Med. 1991;72:455-461.
45. Beierwaltes WH. Update on basic research and clinical experience with metaiodobenzylguanidine. Med Pediatr Oncol. 1987;15:163-169.
46. 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol. 2000;11:1437-1443.
47. 131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. J Nucl Biol Med. 1991;35:295-299.
48. 131I-MIBG). Nucl Med Commun. 1987;8:643-653.
49. Shapiro B, Sisson JC, Wieland DM, et al. Radiopharmaceutical therapy of malignant pheochromocytoma: results from ten years of experience. J Nucl Biol Med. 1991;35:269-276.
50. Khafagi FA, Shapiro B, Fig LM, et al. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med. 1989;30:481-489.
51. Wafelman AR, Hoefnagel CA, Maes RAA, et al. Radioinated metaiodobenzylguanidine: a review of pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545-559.
52. Brans B, Monsieurs M, Laureys G, et al. Thyroidal uptake and radiation dose after repetitive I-131-MIBG1 treatments: influence of potassium iodine for thyroid blocking. Med Pediatr Oncol. 2002;38:41-46.
53. 131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer. 2002;94:2081-2089.
54. Lewington VJ, Zivanovic MA, Tristam M, et al. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. J Nucl Biol Med. 1991;35:280-283.
55. Lumbroso J, Schlumberger M, Tenebaum F, et al. [131]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma. J Nucl Biol Med. 1991;35:288-291.
56. Fisher M. Therapy of pheochromocytoma with [131]metaiodobenzylguanidine. J Nucl Biol Med. 1991;35:292-294.
57. Bestagno M, Pizzocaro C, Maira G, et al. Results of [131]metaiodobenzylguanidine treatment in malignant pheochromocytoma. J Nucl Biol Med. 1991;35:277-279.
58. 131]metaiodobenzylguanidine therapy administered in metastatic malignant pheochromocytoma. J Nucl Biol Med. 1991;35:300-304.
59. 131]metaiodobenzylguanidine therapy administered to three patients with malignant pheochromocytoma. J Nucl Biol Med 1991;35:305-307.
60. 131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med. 1991;35:305-307.
61. 131I]metaiodobenzylguanidine in the Treatment of Neural Crest Tumors. Rome; 1991:42.
62. Ball AB, Tait DM, Fisher C, et al. Treatment of metastatic para-aortic paraganglioma by surgery, radiotherapy and 131IMIBG. Eur J Surg Oncol. 1991;17:543-546.
63. 131I]metaiodobenzylguanidine treatment of a malignant paraganglioma. J Nucl Biol Med. 1991;35:313-314.
64. 131-I-Meta-Iodobenzylguanidine for the diagnosis and treatment of pheochromocytoma. Panminerva Med. 1988;30:169-172.
65. Pujol P, Bringer J, Faurous P, et al. Metastatic phaeochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy. Eur J Nucl Med. 1995;22:382-384.
66. 131I-MIBG. Med Ped Oncol. 1990;18:126-130.
67. Theilade K, Bak M, Olsen K, et al. A case of malignant pheochromocytoma treated by 131I-metaiodobenzylguanidine. Acta Oncol. 1988;27: 296-297.
68. Guo J-Z, Gong L-S, Chen S-X, et al. Malignant pheochromocytoma: diagnosis and treatment in fifteen cases. J Hypertens. 1989;7:261-266.
69. 131I]-Meta-iodobenzylguanidine in treatment of malignant pheochromocytomas. Lancet. 1983;2:107.
70. 131I-MIBG. Ann Nucl Med. 1994;8:259-268.
71. 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer institute of Milan. Q J Nucl Med. 2000;44: 77-87.
72. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma. Ann Nucl Med. 1994;8:133-137.
73. 131I-metaiodobenzylguanidine and a combined chemotherapy with cyclophosphamide, vincristine and dacarbazine. Endocr J. 1994;41:155-160.
74. 131 MIBG scanning. Clin Nucl Med. 1996;21:960-963.
75. Shapiro B, Sisson JC, Shulkin BL, et al. The current status of radioiodinated metaiodobenzylguanidine therapy of neuro-endocrine tumors. Q J Nucl Med. 1995;39:55-57.
76. 131-I metaiodobenzylguanidine. Eur J Nucl Med. 1988;14:337-340.
77. Sisson JC, Shapiro B, Hutchinson RJ, et al. Predictor of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med. 1994;21:46-52.
78. Lewington VJ, Zivanovic MA, Tristam M, et al. Radiolabeled metaiodobenzylguanidine targeted radiotherapy for malignant pheochromocytoma. J Nucl Biol Med. 1991;35:280-283.
79. Bongers V, de Klerk JMH, Zonnenberg BA, et al. Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors. J Nucl Med. 1997;38:1024-1026.
80. Dahllof G, Borgstrom P, Lundell G, et al. Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with a neuroblastoma. Oral Surg Oral Med Oral Pathol Radiol Endod. 2001;92:420-423.
81. Dwamena BA, Zempel S, Klopper JF, et al. Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma. Clin Nucl Med. 1998;23:441-445.
82. 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol. 1999;22:356-370.
83. Hartley A, Spooner D, Brunt AM. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol (R Coll Radiol). 2001;13:361-366.
84. Yanik G, Levine JE, Matthay K, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for treatment of neuroblastoma. J Clin Oncol. 2002;20:2142-2149.
85. 131I-labeled MIBG and the combination. Eur J Gastroenterol Hepatol. 1999;11:1157-1164.
86. Adams S, Acker P, Lorenz M, et al. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma. Cancer. 2001;92:263-270.